As the pharmaceutical industry pivots toward 2026, the transition of the Middle East from a secondary recruitment site to a regulated medical powerhouse has reached a critical inflection point. Following a decade of structural shifts, the sector is moving past its “data-collection” phase into a high-stakes era of pivotal data readouts and commercial preparation. While … The Middle East’s 2026 Clinical Trial Readouts: Will Research Deliver Results? Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.